Flunarizine
As of the edition of 20 October 2026, Flunarizine is a small molecule: marketed, first approved in 1981 (ES); acts on CACNA1G, CACNA1H and CACNA1I.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2002
- Kind
- Small molecule
- Brand name
- Sibelium
- First approved
- 1 January 1981 (ES)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- AA PHARMA INC; 3 holders in all
- Registered trials
- 14, 1 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 0 | 3 | 0 |
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 2 | 0 | 1 | 1 |
| Phase 4 | 6 | 4 | 1 | 0 |
| All trials | 14 |